Tissue plasminogen activator vs heparin for locking central venous catheters between apheresis procedures. 2019

Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
Department of Pathology, Saint Luke's Health System, Kansas City, Missouri.

BACKGROUND Central venous catheters (CVCs) for apheresis procedures require regular locking/flushes to maintain adequate flow rates. Literature comparing locking solutions for apheresis, where the time interval between procedures can be longer than for hemodialysis (many days to weeks), is lacking. In this study, catheter malfunction rates using recombinant tissue plasminogen activator (rt-PA) vs heparin for locking CVC between apheresis procedures were compared. METHODS A retrospective review of 93 extracorporeal photopheresis procedures in 10 patients was performed at our institution. About 1000 U/mL heparin or 2 mg rt-PA was used as the locking solution. Heparin locks were changed at least once per week and rt-PA locks could be left in place for up to 4 weeks. Following these locks, inadequate blood flow noted on accessing CVC and/or during the procedure was scored on as: no issues, some issues, or significant issues. Binary logistic regression was used to evaluate for potential statistical difference in outcomes. Cost analysis was also performed. RESULTS No statistically significant difference was noted in outcomes between heparin and rt-PA lock (P value = 0.15). Total cost of heparin lock administration ($91-$362.50) was found to be more than rt-PA lock ($76) when more than one flush was needed between procedures. CONCLUSIONS For apheresis use, rt-PA and heparin CVC locks seem to have similar outcomes in preventing CVC malfunction. The convenience of not needing any flushes between procedures and overall cost of administering fewer locks favors rt-PA use when the interval between procedures is >7 days.

UI MeSH Term Description Entries
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D001781 Blood Component Removal Any procedure in which blood is withdrawn from a donor, a portion is separated and retained, at the same time the remainder is returned to the donor. Apheresis,Pheresis,Aphereses,Blood Component Removals,Phereses,Removal, Blood Component
D003902 Detergents Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. Cleansing Agents,Detergent Pods,Laundry Detergent Pods,Laundry Pods,Syndet,Synthetic Detergent,Agent, Cleansing,Agents, Cleansing,Cleansing Agent,Detergent,Detergent Pod,Detergent Pod, Laundry,Detergent Pods, Laundry,Detergent, Synthetic,Detergents, Synthetic,Laundry Detergent Pod,Laundry Pod,Pod, Detergent,Pod, Laundry,Pod, Laundry Detergent,Pods, Detergent,Pods, Laundry,Pods, Laundry Detergent,Synthetic Detergents
D004868 Equipment Failure Failure of equipment to perform to standard. The failure may be due to defects or improper use. Defects, Equipment,Device Failure,Failure, Equipment,Malfunction, Equipment,Medical Device Failure,Misuse, Equipment,Device Failure, Medical,Device Failures, Medical,Failure, Medical Device,Failures, Medical Device,Defect, Equipment,Device Failures,Equipment Defect,Equipment Defects,Equipment Failures,Equipment Malfunction,Equipment Malfunctions,Equipment Misuse,Equipment Misuses,Failure, Device,Failures, Device,Failures, Equipment,Malfunctions, Equipment,Misuses, Equipment
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D062905 Central Venous Catheters Catheters that are inserted into a large central vein such as a SUBCLAVIAN VEIN or FEMORAL VEIN. Central Venous Catheter,Catheter, Central Venous,Catheters, Central Venous,Venous Catheter, Central,Venous Catheters, Central

Related Publications

Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
October 2011, Avicenna journal of medicine,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
June 1998, Medical and pediatric oncology,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
April 2003, Hemodialysis international. International Symposium on Home Hemodialysis,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
January 1990, JPEN. Journal of parenteral and enteral nutrition,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
January 1992, Journal of clinical apheresis,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
August 2017, Journal of clinical apheresis,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
January 1999, Bone marrow transplantation,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
January 2014, Revue de l'infirmiere,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
July 2000, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,
Gagan Mathur, and Sarah L Mott, and Laura Collins, and Annette J Schlueter
February 2010, The Journal of pediatrics,
Copied contents to your clipboard!